Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

Red-Horse, 2007, Endothelium-microenvironment interactions in the developing embryo and in the adult, Dev. Cell, 12, 181, 10.1016/j.devcel.2007.01.013 Ferrara, 2007, Targeting VEGF-A to treat cancer and age-related macular degeneration, Annu. Rev. Med., 58, 491, 10.1146/annurev.med.58.061705.145635 Kerbel, 2008, Tumor angiogenesis, N. Engl. J. Med., 358, 2039, 10.1056/NEJMra0706596 Crawford, 2008, VEGF inhibition: insights from preclinical and clinical studies, Cell Tissue Res., 335, 261, 10.1007/s00441-008-0675-8 Ferrara, 2003, The biology of VEGF and its receptors, Nature Med., 9, 669, 10.1038/nm0603-669 Shibuya, 2006, Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis, Angiogenesis, 9, 225, 10.1007/s10456-006-9055-8 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N. Engl. J. Med., 355, 2542, 10.1056/NEJMoa061884 Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N. Engl. J. Med., 357, 2666, 10.1056/NEJMoa072113 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N. Engl. J. Med., 350, 2335, 10.1056/NEJMoa032691 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N. Engl. J. Med., 356, 125, 10.1056/NEJMoa060655 Bergers, 2008, Modes of resistance to anti-angiogenic therapy, Nat. Rev. Cancer, 8, 592, 10.1038/nrc2442 Motzer, 2007, Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, N. Engl. J. Med., 356, 115, 10.1056/NEJMoa065044 Ellis, 2008, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nat. Rev. Cancer, 8, 579, 10.1038/nrc2403 Chen, 2009, Antiangiogenic clinical strategies: Adverse effects of anticancer agents that target the VEGF pathway, Nat. Rev. Clin. Oncol, 6, 465, 10.1038/nrclinonc.2009.94 Shojaei, 2008, Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies, Drug Resist. Update, 11, 219, 10.1016/j.drup.2008.09.001 Yu, 2002, Effect of p53 status on tumor response to antiangiogenic therapy, Science, 295, 1526, 10.1126/science.1068327 Shibuya, 2008, Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis, BMB Rep., 41, 278, 10.5483/BMBRep.2008.41.4.278 Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, 284, 1994, 10.1126/science.284.5422.1994 Rubenstein, 2000, Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption, Neoplasia, 2, 306, 10.1038/sj.neo.7900102 Ninomiya, 2009, Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice, J. Surg. Res., 154, 196, 10.1016/j.jss.2008.08.017 Padera, 2008, Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib, Mol. Cancer Ther., 7, 2272, 10.1158/1535-7163.MCT-08-0182 Lang, 2008, Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes, Mol. Cancer Ther., 7, 3509, 10.1158/1535-7163.MCT-08-0373 Matsui, 2008, Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase, Clin. Cancer Res., 14, 5459, 10.1158/1078-0432.CCR-07-5270 Verheul, 2007, Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model, Clin. Cancer Res., 13, 4201, 10.1158/1078-0432.CCR-06-2553 Matsumori, 2006, ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model, Oncol. Res., 16, 15, 10.3727/000000006783981260 Huang, 2003, Regression of established tumors and metastases by potent vascular endothelial growth factor blockade, Proc. Natl. Acad. Sci. U S A, 100, 7785, 10.1073/pnas.1432908100 Sweeney, 2002, Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production, Clin. Cancer Res., 8, 2714 Rowe, 2000, Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms’ tumor, J. Pediat. Surg., 35, 30, 10.1016/S0022-3468(00)80008-1 Inoue, 2000, Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel, Clin. Cancer Res., 6, 2635 Shaheen, 1999, Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis, Cancer Res., 59, 5412 Melnyk, 1999, Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model, J Urol, 161, 960, 10.1016/S0022-5347(01)61829-9 Warren, 1995, Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis, J. Clin. Invest., 95, 1789, 10.1172/JCI117857 Paez-Ribes, 2009, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, Cancer Cell, 15, 220, 10.1016/j.ccr.2009.01.027 Ebos, 2009, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis, Cancer Cell, 15, 232, 10.1016/j.ccr.2009.01.021 Ebos, 2007, Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy, Proc. Natl. Acad. Sci. U S A, 104, 17064, 10.1073/pnas.0708148104 Brahimi-Horn, 2007, Hypoxia and cancer, J Mol Med, 85, 1301, 10.1007/s00109-007-0281-3 Knudsen, 2008, Showering c-MET-dependent cancers with drugs, Curr. Opin. Genet. Dev., 18, 87, 10.1016/j.gde.2008.02.001 Gandhi, 2009, Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis, Cancer Prev. Res. (Phila. Pa.), 2, 330, 10.1158/1940-6207.CAPR-08-0213 Inoue, 2002, VEGF-A has a critical, non redundant role in angiogenic swithing and pancreatic b cell carcinogenesis, Cancer Cell, 1, 193, 10.1016/S1535-6108(02)00031-4 Wolmark, N. et al. (2009) A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J. Clin. Oncol. 27, 18s.(suppl: abstract LBA4) Maglione, 1991, Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor, Proc. Natl. Acad. Sci. U S A, 88, 9267, 10.1073/pnas.88.20.9267 Park, 1994, Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR, J. Biol. Chem, 269, 25646, 10.1016/S0021-9258(18)47298-5 Batchelor, 2007, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell, 11, 83, 10.1016/j.ccr.2006.11.021 Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J. Clin. Oncol., 24, 16, 10.1200/JCO.2005.02.2574 Fischer, 2007, Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels, Cell, 131, 463, 10.1016/j.cell.2007.08.038 Shojaei, 2007, Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells, Nature Biotechnol., 25, 911, 10.1038/nbt1323 Casanovas, 2005, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, 8, 299, 10.1016/j.ccr.2005.09.005 Alitalo, 2005, Lymphangiogenesis in development and human disease, Nature, 438, 946, 10.1038/nature04480 Tammela, 2008, Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation, Nature, 454, 656, 10.1038/nature07083 Neufeld, 2002, The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis, Trends Cardiovas. Med., 12, 13, 10.1016/S1050-1738(01)00140-2 Pan, 2007, Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth, Cancer Cell, 11, 53, 10.1016/j.ccr.2006.10.018 Yuan, 2002, Abnormal lymphatic vessel development in neuropilin 2 mutant mice, Development, 129, 4797, 10.1242/dev.129.20.4797 Karpanen, 2006, Functional interaction of VEGF-C and VEGF-D with neuropilin receptors, FASEB J., 20, 1462, 10.1096/fj.05-5646com Caunt, 2008, Blocking neuropilin-2 function inhibits tumor cell metastasis, Cancer Cell, 13, 331, 10.1016/j.ccr.2008.01.029 He, 2005, Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels, Cancer Res., 65, 4739, 10.1158/0008-5472.CAN-04-4576 Beenken, 2009, The FGF family: biology, pathophysiology and therapy, Nat. Rev. Drug Discov., 8, 235, 10.1038/nrd2792 Bikfalvi, 1997, Biological roles of fibroblast growth factor-2, Endocrine Rev., 18, 26, 10.1210/er.18.1.26 Cao, 2008, R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways, J. Mol. Med., 86, 785, 10.1007/s00109-008-0337-z Dufraine, 2008, Notch signaling regulates tumor angiogenesis by diverse mechanisms, Oncogene, 27, 5132, 10.1038/onc.2008.227 Siekmann, 2008, Modulation of VEGF signalling output by the Notch pathway, Bioessays, 30, 303, 10.1002/bies.20736 Siekmann, 2007, Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries, Nature, 445, 781, 10.1038/nature05577 Hellstrom, 2007, Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis, Nature, 445, 776, 10.1038/nature05571 Mailhos, 2001, Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis, Differentiation, 69, 135, 10.1046/j.1432-0436.2001.690207.x Noguera-Troise, 2006, Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis, Nature, 444, 1032, 10.1038/nature05355 Ridgway, 2006, Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis, Nature, 444, 1083, 10.1038/nature05313 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Mantovani, 2008, Tumour immunity: effector response to tumour and role of the microenvironment, Lancet, 371, 771, 10.1016/S0140-6736(08)60241-X Lin, 2007, A cytokine-mediated link between innate immunity, inflammation, and cancer, J. Clin. Invest., 117, 1175, 10.1172/JCI31537 Finak, 2008, Stromal gene expression predicts clinical outcome in breast cancer, Nature Med., 14, 518, 10.1038/nm1764 Orimo, 2006, Stromal fibroblasts in cancer: a novel tumor-promoting cell type, Cell Cycle, 5, 1597, 10.4161/cc.5.15.3112 Nolan, 2007, Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization, Genes Dev., 21, 1546, 10.1101/gad.436307 De Palma, 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors, Cancer Cell, 8, 211, 10.1016/j.ccr.2005.08.002 Dong, 2004, VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis, EMBO J., 23, 2800, 10.1038/sj.emboj.7600289 Grunewald, 2006, VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells, Cell, 124, 175, 10.1016/j.cell.2005.10.036 Orimo, 2005, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, 121, 335, 10.1016/j.cell.2005.02.034 Coussens, 2002, Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science, 295, 2387, 10.1126/science.1067100 Shojaei, 2008, Role of myeloid cells in tumor angiogenesis and growth, Trends Cell Biol., 18, 372, 10.1016/j.tcb.2008.06.003 Crawford, 2009, PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment, Cancer Cell, 15, 21, 10.1016/j.ccr.2008.12.004 Shojaei, 2007, Bv8 regulates myeloid cell-dependent tumour angiogenesis, Nature, 450, 825, 10.1038/nature06348 Serafini, 2006, Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression, Semin. Cancer Biol., 16, 53, 10.1016/j.semcancer.2005.07.005 Diaz-Montero, 2009, Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy, Cancer Immunol. Immunother., 58, 49, 10.1007/s00262-008-0523-4 Marigo, 2008, Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells, Immunol. Rev., 222, 162, 10.1111/j.1600-065X.2008.00602.x Yang, 2004, Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis, Cancer Cell, 6, 409, 10.1016/j.ccr.2004.08.031 LeCouter, 2001, Identification of an angiogenic mitogen selective for endocrine gland endothelium, Nature, 412, 877, 10.1038/35091000 LeCouter, 2004, Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization, Proc. Natl. Acad. Sci. U S A, 101, 16813, 10.1073/pnas.0407697101 Shojaei, 2008, Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression, Proc. Natl. Acad. Sci. U S A, 105, 2640, 10.1073/pnas.0712185105 Shojaei, 2009, G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models, Proc. Natl. Acad. Sci. U S A, 106, 6742, 10.1073/pnas.0902280106 Zhong, 2009, Characterization and Regulation of Bv8 in Human Blood Cells, Clin. Cancer Res., 15, 2675, 10.1158/1078-0432.CCR-08-1954 Bhowmick, 2004, Stromal fibroblasts in cancer initiation and progression, Nature, 432, 332, 10.1038/nature03096 Tejada, 2006, Tumor-driven paracrine PDGF receptor -a signaling is a key determinent of stromal cell recruitment in a model of human lung carcinoma, Clin. Cancer Res., 12, 2676, 10.1158/1078-0432.CCR-05-1770 Farmer, 2009, A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer, Nat. Med., 15, 68, 10.1038/nm.1908 di Tomaso, 2009, PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment, PLoS ONE, 4, e5123, 10.1371/journal.pone.0005123 Ferrara, 2005, Angiogenesis as a therapeutic target, Nature, 438, 967, 10.1038/nature04483 Anderberg, 2009, Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts, Cancer Res., 69, 369, 10.1158/0008-5472.CAN-08-2724 Pietras, 2008, Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting, PLoS Med., 5, e19, 10.1371/journal.pmed.0050019 Lokker, 2002, Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors, Cancer Res., 62, 3729 Bergers, 2003, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, J. Clin. Invest., 111, 1287, 10.1172/JCI200317929 Hainsworth, 2007, Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial, Clin. Genitourin. Cancer, 5, 427, 10.3816/CGC.2007.n.030 Xian, 2006, Pericytes limit tumor cell metastasis, J. Clin. Invest., 116, 642, 10.1172/JCI25705 Loizos, 2005, Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target, Molecular cancer therapeutics, 4, 369, 10.1158/1535-7163.MCT-04-0114